113 related articles for article (PubMed ID: 36814131)
1. A glycosylation signature for predicting the progression and immunotherapeutic response of prostate cancer.
Sun K; Feng Z; Fan C; Min X; Zhang P; Xia L
J Gene Med; 2023 Jun; 25(6):e3489. PubMed ID: 36814131
[TBL] [Abstract][Full Text] [Related]
2. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
3. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
6. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer.
Lv W; Tan Y; Zhou X; Zhang Q; Zhang J; Wu Y
Front Immunol; 2022; 13():989928. PubMed ID: 36189319
[TBL] [Abstract][Full Text] [Related]
7. The cGAS-STING pathway-related gene signature can predict patient prognosis and immunotherapy responses in prostate adenocarcinoma.
Zhuo X; Dai H; Yu S
Medicine (Baltimore); 2022 Dec; 101(50):e31290. PubMed ID: 36550819
[TBL] [Abstract][Full Text] [Related]
8. Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.
Ren X; Chen X; Zhang X; Jiang S; Zhang T; Li G; Lu Z; Zhang D; Wang S; Qin C
Front Immunol; 2021; 12():686809. PubMed ID: 34777331
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
Wu L; Quan W; Yue G; Luo Q; Peng D; Pan Y; Zhang G
BMC Cancer; 2021 Jan; 21(1):15. PubMed ID: 33402116
[TBL] [Abstract][Full Text] [Related]
10. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
11. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
12. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
13. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
[TBL] [Abstract][Full Text] [Related]
14. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
15. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
16. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract][Full Text] [Related]
17. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
[TBL] [Abstract][Full Text] [Related]
18. Characterization of metabolism-associated molecular patterns in prostate cancer.
Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H
BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589
[TBL] [Abstract][Full Text] [Related]
19. [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.
Luo L; Li A; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Yunpeng Y; Li Z; Hong S
Immunol Res; 2023 Apr; 71(2):213-228. PubMed ID: 36434349
[TBL] [Abstract][Full Text] [Related]
20. Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.
Tan X; Cai Z; Chen G; Cai C; Chen J; Liang Y; Zhuo Y; Liu J; Huang L; Ouyang B; Wei Y; Jia Z; Deng J; Zhong W; Lu J
Discov Oncol; 2023 May; 14(1):62. PubMed ID: 37155024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
